Back to top
more

Chemed (CHE)

(Delayed Data from NYSE)

$584.89 USD

584.89
60,722

-1.28 (-0.22%)

Updated Sep 3, 2024 04:00 PM ET

After-Market: $585.47 +0.58 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

GNC Holdings (GNC) Beats on Q1 Earnings, Plans Store Shutdown

GNC Holdings (GNC) announces plans to shutter roughly 200 stores in 2018 as part of the ongoing optimization of the company's store portfolio in Q1.

    Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid

    Stryker (SYK) gains from strong segmental show in Q1; a solid guidance is promising.

      Varian Medical (VAR) Beats Q2 Earnings & Revenue Estimates

      Strong performance in the Software, Hardware and Service revenues boost Varian Medical's (VAR) Q2 results.

        CONMED (CNMD) Beats on Q1 Earnings, Lifts FY18 Guidance

        CONMED (CNMD) gains on strong performance in core segments; raised guidance buoys optimism.

          Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View

          Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.

            Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop

            Zimmer Biomet (ZBH) issues full-year 2018 sales and earnings guidance in Q1.

              Align Technology (ALGN) Beats on Earnings and Revenues in Q1

              Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.

                Chemed (CHE) Beats on Q1 Earnings & Revenues, Retains View

                Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q1.

                  MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE

                  On a positive note, the broader healthcare looks delighted with the massive tax cuts. Also, the scenario within the Medical Device space seems equally bright.

                    Chemed (CHE) Beats on Q4 Earnings & Revenues, Issues View

                    Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q4.

                      Will Envision Healthcare's Growth Strategies Help the Stock?

                      Envision Healthcare (EVHC) is expected to gain from is a number of long term growth strategies.

                        New Year to Bring Back MedTech Tax, 3 Stocks Unfazed

                        Investors are apprehensive about the re-enactment of MedTech Tax and related concerns, despite raking in returns from other sectors.

                          4 Reasons Why Envision Healthcare (EVHC) Looks Dull

                          Envision Healthcare continues to suffer from low patient volumes, increased leverage, high operating expense and a weak operating environment.

                            Zimmer Biomet Strong on Positive Data From PROGRESS II Study

                            Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.

                              Here's Why You Should Invest in Masimo (MASI) Right Now

                              Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.

                                Haemonetics Banks on Hospital Business, Competition Rife

                                For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.

                                  Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart

                                  Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart

                                    Tirthankar Chakraborty headshot

                                    5 of the Best Efficient Stocks to Strengthen Your Portfolio

                                    We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

                                      4 Growth Stocks to Pick From a Choppy MedTech Market

                                      In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.

                                        DaVita (DVA) Surges: Stock Moves 13.6% Higher

                                        DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes

                                          Chemed Banks on Roto-Rooter Sales, Focuses on Vitas Revival

                                          Chemed (CHE) continues to display robust performance in Roto-Rooter business on strength in core plumbing and drain cleaning service segments.

                                            Align Technology Rides High on InvisAlign & Strategic Pacts

                                            Rising demand for InvisAlign products in the global teen market and the distribution agreement with Patterson Dental are major upsides for Align (ALGN).

                                              Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources

                                              Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources

                                                Tirthankar Chakraborty headshot

                                                5 of the Most Efficient Stocks to Boost Your Portfolio

                                                Company with a favorable efficiency level generally provides impressive returns as it is believed to be positively correlated with the stock's price performance.

                                                  Envision Healthcare Down More Than 50% This Year, Here's Why

                                                  Envision Healthcare (EVHC) seems to be bogged down by soft patient volumes, increasing expenses and high leverage.